GGrantIndex
← Search

Radiation Biology Research Program (Project-003)

$43,896P30FY2018CANIH

Stanford University, Stanford CA

Investigators

Linked publications, trials & patents

Paper 39574895Paper 39534431Paper 39506045Paper 39378093Paper 39257774Paper 39179931Paper 39163262Paper 39132489Paper 39042439Paper 38997156Paper 38996463Paper 38987048Paper 38968138Paper 38838737Paper 38810650Paper 38746193Paper 38563850Paper 38496616Paper 38496500Paper 38408498Paper 38387457Paper 38278150Paper 38273211Paper 38262408Paper 38260330Paper 38200310Paper 38154193Paper 38096469Paper 37963187Paper 37917579Paper 37882771Paper 37812494Paper 37743567Paper 37667254Paper 37662553Paper 37534980Paper 37532139Paper 37527449Paper 37398193Paper 37244414Paper 37196642Paper 37184546Paper 37162847Paper 36999999Paper 36993756Paper 36813894Paper 36747642Paper 36734849Paper 36729432Paper 36729074Paper 36719070Paper 36717409Paper 36711732Paper 36701540Paper 36652552Paper 36640300Paper 36635501Paper 36624348Trial NCT05220254Trial NCT03733210Trial NCT03405142Trial NCT03241940Trial NCT03179449Trial NCT02855086Trial NCT02805075Trial NCT02762266Trial NCT02736578Trial NCT02735356Trial NCT02699723Trial NCT02695628Trial NCT02690948Trial NCT02683824Trial NCT02635074Trial NCT02624518Trial NCT02599194Trial NCT02581787Trial NCT02488070Trial NCT02440308Trial NCT02432118Trial NCT02429804Trial NCT02415608Trial NCT02401347Trial NCT02215928Trial NCT02210858Trial NCT02203565Trial NCT02184533Trial NCT02175745Trial NCT02166983Trial NCT02058550Trial NCT02030405Trial NCT02019069Trial NCT01977677Trial NCT01943188Trial NCT01928030Trial NCT01926990Trial NCT01908166Trial NCT01904643Trial NCT01898403Trial NCT01893892Trial NCT01868503

Abstract

PROJECT SUMMARY ? RADIATION BIOLOGY PROGRAM The Program in Radiation Biology is focused on ways in which the effectiveness of radiotherapy can increase both local tumor control and the survival of cancer patients. The members of this program investigate new ways to enhance the efficacy of radiotherapy by targeting the tumor microenvironment, protecting normal tissue from radiation toxicity, and developing new technology to deliver radiation in a focused manner at high speed. To achieve these goals, basic discovery science, high throughput screening and preclinical models are used to obtain critical supporting data to take these approaches into clinical trials. Thus, the program includes both basic and translational science. Program research is focused on two major scientific aims: Aim 1: To develop pharmacologic and biologic agents to combine with radiotherapy to improve local tumor control and prevent metastatic spread. These studies are focused on developing new approaches to improve local control with radiotherapy, protect normal tissues from radiation toxicity, and identify genetic determinants that influence the response of tumors to DNA damage and modulate tissue integrity. Aim 2: To develop new approaches to administer radiotherapy or combined modality therapy to test in clinical trials. These investigations employ diverse approaches that include the use of functional imaging to more selectively deliver radiotherapy, expand the uses of hypofractionated radiotherapy, and develop new technologies that can deliver high-energy electrons in less than a second. The program is co-led by Amato Giaccia, PhD and Quynh Le, MD. The 25 members of this program represent the School of Medicine and the School of Humanities and Sciences, and are supported by peer-reviewed research totaling $8.0M, including 21 R01s, 1P01s, and 2 T32s. Peer-reviewed funding consists of $4.7M from the NCI, other NIH support amounts to $2.5M, and other peer-reviewed support to $0.9M. The members of this program are highly motivated and interactive in their goal to take fundamental discoveries in the laboratory and develop them to increase the efficacy of radiotherapy to control tumor growth and metastasis. Since 2009, members of the Radiation Biology Program published 450 manuscripts, a near doubling from the last submission. Of these, 31% represent intra- programmatic collaborations and 33% represent inter-programmatic collaborations. The Stanford Cancer Institute enhances the program's goals by providing state-of-the-art shared resources, seed grant support for new projects, programmatic funds, retreats, special seminars, and support for new recruitments. The support from the SCI has been instrumental in promoting both intra- and inter- programmatic collaborations that were essential for the renewal of our program project grant on tumor hypoxia, the development of a new program project grant on tissue radioprotection, and the renewal of our T32 training grant to train postdoctoral fellows.

View original record on NIH RePORTER →